调强放射治疗同步替吉奥治疗高龄食管癌患者的疗效观察

Clinical Analysis of Elderly Esophageal Cancer Patients Treated with Intensity Modulated Radiation Therapy and Tegafur Gimeracil Oteracil Potassium Capsule

目的:探讨常规分割调强放射治疗同步替吉奥治疗高龄食管癌患者的疗效。方法:选择2011年10月-2013年10月门诊和住院治疗的高龄食管癌患者53例。根据治疗模式不同,分为同步组和对照组,同步组采用调强放射治疗同步替吉奥治疗,对照组采用单纯调强放射治疗。结果:同步组较对照组的副反应略高,但差异无统计学意义(P>0.05);同步组和对照组患者总有效率分别达到84.00%和57.14%,差异有统计学意义(P=0.033);同步组和对照组患者12个月随访期内的中位无进展生存期分别为10.84个月和9.36个月,差异有统计学意义(P=0.044),同步组和对照组患者的1年生存率分别为88.0%和85.7%,差异无统计学意义(P=0.75)。结论:调强放射治疗同步替吉奥治疗高龄食管癌患者的疗效肯定。

Objective：To study the clinical analysis of elderly esophageal cancer patients treated with intensity modulated radiation therapy（IMRT） and Tegafur Gimeracil Oteracil Potassium Capsule.Method：53 elderly esophageal cancer patients from October 2011 to October 2013 were selected. According to the different treatment modalities,they were divided into the synchronous chemotherapy group and the control group,the synchronous chemotherapy group was treated with IMRT and Tegafur Gimeracil Oteracil Potassium Capsule,the control group was treated with IMRT.Result：The side effects of the synchronous chemotherapy group was higher than that of the control group,but the difference had no significant difference between two groups（P〉0.05）;the total effective rate of the synchronous chemotherapy group was 84.00%,the control group was 57.14%,there was statistically significant difference（P=0.033）,the median progression free survival of the synchronous chemotherapy group and control group were 10.84 months and 9.36 months,there was statistically significant difference（P=0.044）,the survival rate in one year of the synchronous chemotherapy group and control group were 88.0%and 85.7%,there was no statistically significant difference（P=0.75）.Conclusion：Effectiveness of elderly esophageal cancer patients treated with IMRT and Tegafur Gimeracil Oteracil Potassium Capsule is definite.